DOSAGE REGIMES FOR THE ADMINISTRATION OF A LAG-3/PD-L1 BISPECIFIC ANTIBODY

DOSAGE REGIMES FOR THE ADMINISTRATION OF A LAG-3/PD-L1 BISPECIFIC ANTIBODY

The application relates to dosage regimes for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients. L'invention concerne des régimes posologiques pour...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KAYITALIRE, LOUIS, SHEPHERD, CHRISTOPHER, HOLZ, JOSEFIN-BEATE, MORROW, MICHELLE, GERMASCHEWSKI, FIONA, LEUNG, KIN-MEI, GLIDDON, DANIEL, GRADINARU, CRISTIAN
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The application relates to dosage regimes for the administration of an antibody molecule which binds programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3) and their medical use in the treatment of cancer in human patients. L'invention concerne des régimes posologiques pour l'administration d'une molécule d'anticorps qui se lie à la mort programmée 1 (PD-L1) et au gène 3 d'activation des lymphocytes (LAG-3) et leur utilisation médicale dans le traitement du cancer chez des patients humains.